Boehringer Ingelheim is launching the initial studies of a new weight loss drug developed in collaboration with Gubra, the two companies have announced. 

The Phase I study of BI 3034701, which is the second clinical study in the collaboration between Gubra and Boehringer Ingelheim, is expected to be completed in the second half of 2025. 

”The global prevalence of obesity is on the rise and there is a real need for innovative treatments to tackle this complex, chronic disease. This triple agonist is a drug candidate targeting receptors known to induce weight loss and has the potential to become a next-generation, first-in-class treatment for millions of people worldwide,” said Henrik Blou, CEO of Gubra. 

BI 3034701 was developed through a collaboration between Gubra and Boehringer Ingelheim, with the latter having sole responsibility for the further development and global commercialization of the drug candidate.

English edit: Catherine Brett